Last $1.34 USD
Change Today 0.0001 / 0.01%
Volume 86.6K
BIOD On Other Exchanges
Symbol
Exchange
BIOD is not on other exchanges.
As of 2:03 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

biodel inc (BIOD) Snapshot

Open
$1.36
Previous Close
$1.34
Day High
$1.36
Day Low
$1.33
52 Week High
03/6/14 - $3.71
52 Week Low
10/14/14 - $1.20
Market Cap
32.2M
Average Volume 10 Days
129.2K
EPS TTM
$-0.74
Shares Outstanding
24.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIODEL INC (BIOD)

Related News

No related news articles were found.

biodel inc (BIOD) Related Businessweek News

No Related Businessweek News Found

biodel inc (BIOD) Details

Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.

30 Employees
Last Reported Date: 12/19/14
Founded in 2003

biodel inc (BIOD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $688.4K
Chief Medical Officer
Total Annual Compensation: $437.0K
Chief Administrative Officer, Vice President ...
Total Annual Compensation: $334.2K
Compensation as of Fiscal Year 2014.

biodel inc (BIOD) Key Developments

Biodel Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014

Biodel Inc. reported unaudited consolidated financial results for the first quarter ended December 31, 2014. For the quarter, the company reported a net loss of $2.443 million or $0.12 per basic and diluted share compared to a net loss of $4.7 million or $0.20 per basic and diluted share a year ago. Loss before tax provision was $2.44 million against $4.7 million a year ago.

Biodel Inc. to Report Q1, 2015 Results on Feb 12, 2015

Biodel Inc. announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on Feb 12, 2015

Biodel Inc., Q1 2015 Earnings Call, Feb 12, 2015

Biodel Inc., Q1 2015 Earnings Call, Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOD:US $1.34 USD 0.0001

BIOD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOD.
View Industry Companies
 

Industry Analysis

BIOD

Industry Average

Valuation BIOD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIODEL INC, please visit www.biodel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.